
OR WAIT null SECS
Children receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.
Once-monthly intradermal PVX108, a T-cell epitope peptide immunotherapy, increased the maximum tolerated peanut dose vs placebo in children aged 4 to 11 years with peanut allergy in a phase 2 trial, according to Aravax.² The data were presented as a late-breaking oral abstract at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix, Arizona.¹
The randomized, double-blind, placebo-controlled AVX-201 trial enrolled 71 children across 14 sites in the US and Australia and compared 5 nmol and 50 nmol doses with placebo over 12 months.² The 50 nmol group showed a 2.4-fold increase in maximum tolerated dose from baseline vs a 1.2-fold increase with placebo.² At month 12, 39.4% of participants receiving 50 nmol tolerated a cumulative dose of at least 443 mg of peanut protein, compared with 16.7% receiving placebo.²
No treatment-related allergic adverse events, anaphylaxis, or treatment-related serious adverse events occurred at either dose, according to the company.² A follow-up food challenge after a 6-month treatment-free period showed maintenance or improvement in clinical effects at month 18, and 59 of 68 completers (87%) entered a 12-month open-label extension.² PVX108 holds FDA Fast Track designation for the treatment of peanut allergy.²
In the following Q&A, Brian P. Vickery, MD, chief of allergy and immunology at Children’s Healthcare of Atlanta and professor and vice-chair of pediatric clinical research at Emory University School of Medicine, discusses the dose findings, the peptide approach to safety, the durability of effect of treatment, and what phase 3 will need to show.
Brian P. Vickery, MD: The primary efficacy endpoint showed that, after 1 year of treatment, children in the 50 nmol group were able to significantly increase the amount of peanut protein tolerated during an oral food challenge by 2.4-fold, compared to the amount tolerated during a pre-treatment oral food challenge. In another analysis, 39% of these participants were able to tolerate ≥ 300 mg of peanut protein during the post-treatment challenge. This could be enough of a change to protect some of these participants from accidental peanut exposures, which average between 100 - 150 mg.
Brian P. Vickery, MD: The 50 nmol dose outperformed the 5 nmol dose, which is unlikely to be further developed.
Brian P. Vickery, MD: PVX108 consists of 7 synthetic peptide fragments, which are designed to interact with the T cells that orchestrate allergic inflammation while being too small to interact with IgE. Therefore, PVX108 should not trigger acute allergic reactions, unlike other forms of immunotherapy using intact allergens. Consistent with this, there were no treatment-related allergic reactions or anaphylaxis seen in this study or in the previously published phase 1 study in peanut-allergic adults.
Brian P. Vickery, MD: All participants were treated for 12 months and then treatment was stopped following the post-treatment oral food challenges. Then participants abstained from further treatment for 6 months and returned to the research unit for follow-up challenges at month 18 to determine if any of the treatment benefit was sustained. Over half of the month 12 responders sustained or even improved their challenge performance at month 18, which suggests the potential for long-term benefit.
Brian P. Vickery, MD: This study was small, with fewer than 25 participants in each arm, and used an appropriate statistical analysis strategy for small, early-stage studies. Going into phase 3, the study will be substantially larger and will need to replicate or even surpass the efficacy results seen here, while at the same time requiring a more robust statistical analysis.
Brian P. Vickery, MD: PVX108 also lessened the severity of allergic symptoms during the post-treatment food challenge reactions and was associated with improvement in self-reported quality of life in participants aged 8-11 years, as reported by the FAQLQ-Child Form.
References
Related Content: